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journal homepage: www.e- jmii .comCORRESPONDENCEArteriovenous fistula-related bacteremia
caused by Achromobacter xylosoxidans
in a uremic patientDear Editor,
Achromobacter xylosoxidans has been reported to cause
intravascular catheter-related bacteremia in a hemodialy-
sis unit.1,2 Here, we describe a uremic patient with recur-
rent A. xylosoxidans bacteremia due to infected aneurysm
of arteriovenous (AV) fistula.
A 72-year-old female patient presented to the hospital
with fever, chills, and a protruding mass-like lesion over the
left arm AV fistula on December 8, 2013. The patient had
hepatocellular carcinoma and underwent transhepatic
arterioembolization 18 months prior to admission. She also
had chronic renal failure and received hemodialysis through
an AV fistula in the left forearm for 4 years. The first
episode of A. xylosoxidans (Isolate A) bacteremia occurred
on June 12, 2013. She received antibiotic therapy with
ceftazidine 2 g/day intravenously for 14 days. Unfortu-
nately, two additional episodes of bacteremia due to A.
xylosoxidans were detected on July 29, 2013 (Isolate B),
and October 15, 2013 (Isolate C) 2013. Physical examination
revealed redness, swelling, local heat, and tenderness over
the AV fistula site of the left forearm. Sonography exami-
nation found intravascular thrombus of the infected aneu-
rysm of the left forearm. The patient underwent
phlebectomy and surgical debridement of the intravascular
thrombus. Culture of specimens of debrided thrombus
(Isolate D) and two sets of blood cultures obtained from
peripheral venous blood (Isolate E) all yielded A. xylosox-
idans. The susceptibility profiles of the five isolates were
determined by Becton Dickinson Phoenix, Arizona, USA
(automachine for bacteria identification) were identical:
resistant to aminoglycosides, aztreonam, ampicillin, cefe-
pime, cefotaxime, flomoxef, ertapenem, ciprofloxacin, and
levofloxacin, but susceptible to doripenem, meropenem,
imipenem, cefoperazone/sulbactam, tigecycline, colistin,
and trimethoprimesulfamethoxazole. Pulse-field gel elec-
trophoresis of the five isolates with digestion by XbaIhttp://dx.doi.org/10.1016/j.jmii.2014.03.011
1684-1182/Copyright ª 2014, Taiwan Society of Microbiology. Publisheenzyme was performed.3 The pulsotypes of the five isolates
were identical, indicating that they belonged to the same
strains. The patient received combination therapy with
intravenous colistin 2 MU/day and intravenous trimetho-
primesulfamethoxazole 160 mg/800 mg/day. Two sets of
blood cultures taken 7 days after antibiotic treatment were
negative and the patient received an 8-week course of
antibiotic therapy. Whole body gallium scanning and bone
scans were performed during hospitalization and two sets
of blood cultures taken 4 weeks after discharge all revealed
negative findings, indicating the absence of any metastatic
lesions or relapses of bacteremia.
Although patients who receive hemodialysis are at a
potential risk of methicillin-resistant Staphylococcus
aureus bacteremia,1,2 Gram-negative bacteria, especially
non-glucose-fermenting organisms, are increasingly
emerging in nosocomial infection in immunocompromised
patients.1,2,4,5 A. xylosoxidans is found in an aqueous
environment, and is isolated from a wide range of clinical
specimens.1,4,5 A. xylosoxidans is an opportunistic path-
ogen with relatively low virulence, but it can be the caus-
ative agent of complicated bacteremia and nosocomial
infections.1,4,5 To the best of our knowledge, this recurrent
infection in our hemodialysis patient with infected aneu-
rysm of AV fistula due to A. xylosoxidans is the first case
report. Many microbiological methods, such as antibiogram,
biotying, random amplified polymorphic DNA, pulse-field
gel electrophoresis,1,3,4 have been proposed to identify A.
xylosoxidans. The molecular typing techniques are
preferred for differentiating strains in epidemiological and
cluster studies.1,3,6
Management of infected aneurysm of AV fistula or per-
manent catheter-related bacteremia is controversial.1,2,4
The decision to remove the catheter or surgical debride-
ment is difficult, particularly in patients with limited
venous access. The experience of AV fistula infection due to
A. xylosoxidans is rare, therefore, clinicians should assessd by Elsevier Taiwan LLC. All rights reserved.
Correspondence 579the complications such as endocarditis, septic thrombosis,
tunnel infection, biofilm formation, or metastatic seed-
ing.1,4,5,7 Based on our experience of this patient, we sug-
gest that patients with infected aneurysm of AV fistula due
to A. xylosoxidans bacteremia can be successfully treated
with systemic combination antimicrobial therapy plus
phlebectomy with intravascular removal of thrombus.
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